This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: There is ongoing controversy about the effects of methylmercury (MeHg) exposure from fish consumption on child development. We previously reported no adverse developmental outcomes in children tested at 5.5 years of age following both prenatal and postnatal exposure from fish consumption in our longitudinal study in the Seychelles Islands.¹ A similar study in the Faeroe Islands reported subtle adverse effects associated with prenatal exposure from consumption of both fish and pilot whales.²

A National Academy of Sciences panel recently reviewed the evidence for health risks from dietary MeHg exposure.³ The review included both the Seychelles and Faeroes studies. The panel concluded that both studies were well designed, controlled, and executed, and that a variety of differences, including methodological, might account for the difference in results. The panel made 2 suggestions concerning the analysis of our 5.5-year test scores: (1) the use of raw test scores instead of . . . [Full Text of this Article]

Methods



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Linezolid for the treatment of multidrug-resistant tuberculosis
Fortun et al.
J Antimicrob Chemother 2005;56:180-185.
ABSTRACT | FULL TEXT  

Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study
Senneville et al.
J Antimicrob Chemother 2004;54:798-802.
ABSTRACT | FULL TEXT  

Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin {alpha}, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates
Petersen et al.
Antimicrob. Agents Chemother. 2004;48:739-746.
ABSTRACT | FULL TEXT  

Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies
Rubinstein et al.
Antimicrob. Agents Chemother. 2003;47:1824-1831.
ABSTRACT | FULL TEXT  

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia
Smith et al.
Ann Oncol 2003;14:795-801.
ABSTRACT | FULL TEXT  

Mechanisms for Linezolid-Induced Anemia and Thrombocytopenia
Bernstein et al.
The Annals of Pharmacotherapy 2003;37:517-520.
ABSTRACT | FULL TEXT